Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival

Clinical Cancer Research

Volumn 21, Issue 17, 2015, Pages 3879-3887

  Reed, Caroline M ^a   Cresce, Nicole D ^a   Mauldin, Ileana S ^a   Slingluff, Craig L ^a   Olson, Walter C ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; MELANOMA ANTIGEN; MELANOMA HELPER PEPTIDE; MELANOMA VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; EPITOPE; PEPTIDE;

ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TH1 CELL; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; BLOOD; CHEMISTRY; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; METABOLISM; MORTALITY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TIME FACTOR; TREATMENT OUTCOME; VACCINATION;

AMINO ACID SEQUENCE; ANTIBODY FORMATION; CANCER VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; NEOPLASM STAGING; PEPTIDES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84942540894     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0233     Document Type: Article

References (42)

1. Swartz A, Batich K, Fecci P, Sampson J. Peptide vaccines for the treatment of glioblastoma. J Neurooncol 2014 2014 Dec 10. [Epub ahead of print].
2. Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 2011; 17: 343-50.
3. Dillon P, Olson W, Czarkowski A, Petroni G, Smolkin M, Grosh W, et al. A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. J Immunother Cancer 2014; 2: 23.
4. Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008; 26: 4973-80.
5. Kobold S, Lütkens T, Cao Y, Bokemeyer C, Atanackovic D. Autoantibodies against tumor-related antigens: Incidence and biologic significance. Human Immunology 2010; 71: 643-51.
6. Jensen-Jarolim E, Singer J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines 2011; 10: 1281-9.
7. Zörnig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, et al. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer 2015; 136: 138-51.
8. Komatsu N, Jackson HM, Chan K, Oveissi S, Cebon J, Itoh K, et al. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein. Mol Immunol 2013; 54: 465-71.
9. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, et al. NY-ESO-1: Review of an immunogenic tumor antigen. In: George F, V, editor. Advances in Cancer Research. Volume 95. Waltham, MA: Academic Press; 2006. p. 1-30.
10. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187: 1349-54.
11. Jäger E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jäger D, et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events. Int J Cancer 1999; 84: 506-10.
12. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci U S A 2004; 101: 10697-702.
13. Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 2012; 35: 89-97.
14. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci 2011; 108: 16723-8.
15. Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, et al. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother 2014; 37: 84-92.
16. Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, et al. Combination immunotherapy after ASCT for multiple myeloma Using MAGE-A3/poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 2014; 20: 1355-65.
17. Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 2004; 27: 124-35.
18. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008; 181: 776-84.
19. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al. Phase Itrial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012; 18: 6497-508.
20. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 2012; 109: 5797-802.
21. von Mensdorff-Pouilly S. Vaccine-induced antibody responses in patients with carcinoma. Expert Rev Vaccines 2010; 9: 579-94.
22. Namm JP, Li Q, Lao X, Lubman DM, He J, Liu Y, et al. B lymphocytes as effector cells in the immunotherapy of cancer. J Surg Oncol 2012; 105: 431-5.
23. Pandey JP, Kistner-Griffin E, Black L, Namboodiri AM, Iwasaki M, Kasuga Y, et al. IGKC and FcgR genotypes and humoral immunity to HER2 in breast cancer. Immunobiology 2014; 219: 113-7.
24. Matsueda S, Komatsu N, Kusumoto K, Koga S, Yamada A, Kuromatsu R, et al. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. Dev Comp Immunol 2013; 41: 68-76.
25. Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res 2012; 5: 1036-43.
26. Nelson BH CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010; 185: 4977-82.
27. Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends Immunol 2013; 34: 169-73.
28. Fang L, Lowther DE, Meizlish ML, Anderson RCE, Bruce JN, Devine L, et al. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro-Oncology 2013; 15: 1479-90.
29. Zirakzadeh AA, Marits P, Sherif A, Winqvist O. Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. J Immunol 2013; 190: 5847-55.
30. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72: 1070-80.
31. Hu Y, Petroni G, Olson W, Czarkowski A, Smolkin M, Grosh W, et al. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother 2014; 63: 779-86.
32. Gnjatic S, Old LJ, Chen YT. Autoantibodies against cancer antigens. In: Tainsky MA, editor. Tumor Biomarker Discovery. Volume 520. Totowa, NJ: Humana Press; 2009. p. 11-9.
33. ∗0101 tetramers. Clin Cancer Res 2010; 16: 4607-15.
34. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a β-human chorionic gonadotropin peptide vaccine in patients withmetastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002; 8: 2044-51.
35. Slingluff CL, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxicT cells and helperT cells for patients with metastatic melanoma (E1602). Clin Cancer Res 2013; 19: 4228-38.
36. Platzer B, Stout MM, Fiebiger E. Antigen cross-presentation of immune complexes. Front Immunol 2014; 5: 140.
37. Baker K, Rath T, Pyzik M, Blumberg RS. The role of FcRn in antigen presentation. Front Immunol 2014; 5: 408.
38. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJM, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002; 168: 2240-6.
39. Boross P, van Montfoort N, Stapels DAC, van der Poel CE, Bertens C, Meeldijk J, et al. FcRg-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells. J Immunol 2014; 193: 5506-14.
40. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110: 71-9.
41. Clatworthy MR, Aronin CEP, Mathews RJ, Morgan NY, Smith KGC, Germain RN. Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat Med 2014; 20: 1458-63.
42. Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, et al. Suppression of Fc g-receptor-mediated antibody effector function during persistent viral infection. Immunity 2015; 42: 379-90.